Moreover, a recent phase II clinical study (KCSG-LU15-09) of small sample of NSCLC patients harboring um-EGFRm indicated that osimertinib, a third-generation EGFR-TKI, exhibited clinical activity in patients with um-EGFRms. Here, EGFR is linked to non-small cell lung carcinoma.